This litigation handles lawsuits alleging that certain GLP-1 receptor agonists (such as Ozempic) can cause Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
The exact size is then adjusted for your body and the injection site
Meaningful body-weight reductions , though slightly less than in non-diabetic participants a trend also seen with injectable GLP-1 receptor agonists These results show why orforglipron is being closely monitored as a potential long-term oral GLP-1 medication for weight management and metabolic health

Several factors may contribute to dizziness in patients taking GLP-1 medications: Hypoglycaemia (low blood glucose) particularly when GLP-1 agonists are used alongside other glucose-lowering medications such as sulphonylureas or insulin Dehydration resulting from reduced fluid intake due to decreased appetite or from gastrointestinal side effects such as nausea, vomiting, or diarrhoea Orthostatic hypotension a drop in blood pressure upon standing, which may occur due to volume depletion or rapid weight loss Reduced caloric intake significant appetite suppression may lead to inadequate nutrition, potentially causing weakness and dizziness The frequency and severity of dizziness vary between individuals and specific GLP-1 products
Vyvanse may have a lower risk of misuse than some other stimulant drugs
Side Effects : Both medications cause nausea, vomiting, and diarrhea, but rates are slightly higher with Tirzepatide